Patents by Inventor Kai Singbartl

Kai Singbartl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120201799
    Abstract: A method of modifying cells includes removing fluid including cells from a patient, contacting the removed fluid from the patient with at least one surface upon which at least one agent to interact at least one cell receptor is immobilized to modify cells in the fluid, and returning the fluid to the patient. The agent can, for example, be immobilized via covalent bonding or ionic bonding to the at least one surface. The fluid can, for example, be blood or a blood fraction. The agent can, for example, be an agonist, an antagonist or an inverse agonist.
    Type: Application
    Filed: October 7, 2010
    Publication date: August 9, 2012
    Inventors: William J. Federspiel, John Alston Kellum, Kai Singbartl
  • Publication number: 20120077690
    Abstract: This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, long-term dialysis. For example, prediction of long-term dialysis treatment can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of approximately fourteen Days measuring hyaluronic acid, death receptor 5, and/or transforming growth factor ?1 can be used to establish the risk of recovery versus non-recovery in patient's having suffered an acute kidney injury.
    Type: Application
    Filed: September 16, 2011
    Publication date: March 29, 2012
    Inventors: Kai Singbartl, John A. Kellum, JR.
  • Publication number: 20100081148
    Abstract: This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, long-term dialysis. For example, prediction of long-term dialysis treatment can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of hyaluronic acid can be used to determine whether a patient having suffered acute kidney injury will require long-term dialysis.
    Type: Application
    Filed: September 23, 2009
    Publication date: April 1, 2010
    Inventors: Kai Singbartl, John A. Kellum, JR.